Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinson’s Disease

Parkinson’s disease is a complex age-related neurodegenerative disorder. Approximately 90% of Parkinson’s disease cases are idiopathic, of unknown origin. The aetiology of Parkinson’s disease is not fully understood but increasing evidence implies a failure in fundamental cellular processes including mitochondrial dysfunction and increased oxidative stress. To dissect the cellular events underlying idiopathic Parkinson’s disease, we use primary cell lines established from the olfactory mucosa of Parkinson’s disease patients. Previous metabolic and transcriptomic analyses identified deficiencies in stress response pathways in patient-derived cell lines. The aim of this study was to investigate whether these deficiencies manifested as increased susceptibility, as measured by cell viability, to a range of extrinsic stressors. We identified that patient-derived cells are more sensitive to mitochondrial complex I inhibition and hydrogen peroxide induced oxidative stress, than controls. Exposure to low levels (50 nM) of rotenone led to increased apoptosis in patient-derived cells. We identified an endogenous deficit in mitochondrial complex I in patient-derived cells, but this did not directly correlate with rotenone-sensitivity. We further characterized the sensitivity to rotenone and identified that it was partly associated with heat shock protein 27 levels. Finally, transcriptomic analysis following rotenone exposure revealed that patient-derived cells express a diminished response to rotenone-induced stress compared with cells from healthy controls. Our cellular model of idiopathic Parkinson’s disease displays a clear susceptibility phenotype to mitochondrial stress. The determination of molecular mechanisms underpinning this susceptibility may lead to the identification of biomarkers for either disease onset or progression.

[1]  Rudolf Jaenisch,et al.  Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.

[2]  D. Turnbull,et al.  Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.

[3]  C. Chinopoulos,et al.  Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: relevance to Parkinson's disease , 2001, Journal of neurochemistry.

[4]  H. Reichmann,et al.  Primary Skin Fibroblasts as a Model of Parkinson's Disease , 2012, Molecular Neurobiology.

[5]  Christine A. Wells,et al.  NRF2 Activation Restores Disease Related Metabolic Deficiencies in Olfactory Neurosphere-Derived Cells from Patients with Sporadic Parkinson's Disease , 2011, PloS one.

[6]  C. Marsden,et al.  L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.

[7]  H. Shill,et al.  Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders , 2010, Acta Neuropathologica.

[8]  Hideyuki Okano,et al.  iPS cell technologies: significance and applications to CNS regeneration and disease , 2014, Molecular Brain.

[9]  R. Schiestl,et al.  Transcriptome Analysis of a Rotenone Model of Parkinsonism Reveals Complex I-Tied and -Untied Toxicity Mechanisms Common to Neurodegenerative Diseases , 2012, PloS one.

[10]  W. Mandemakers,et al.  A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases , 2007, Journal of Cell Science.

[11]  M. Vila,et al.  Mitochondrial alterations in Parkinson’s disease: new clues , 2008, Journal of neurochemistry.

[12]  K. Shannon,et al.  Alpha‐synuclein in colonic submucosa in early untreated Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[13]  M. Beal,et al.  Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.

[14]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[15]  F. Jiménez-Jiménez,et al.  Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease , 2010, BMC neurology.

[16]  A. Mackay-Sim,et al.  New techniques for biopsy and culture of human olfactory epithelial neurons. , 1998, Archives of otolaryngology--head & neck surgery.

[17]  Victor Tapias,et al.  A highly reproducible rotenone model of Parkinson's disease , 2009, Neurobiology of Disease.

[18]  C. Broeckhoven,et al.  Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? , 2008, Genes, brain, and behavior.

[19]  N. Osborne,et al.  Partial mitochondrial complex I inhibition induces oxidative damage and perturbs glutamate transport in primary retinal cultures. Relevance to Leber Hereditary Optic Neuropathy (LHON) , 2006, Neurobiology of Disease.

[20]  R. Benecke,et al.  Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.

[21]  A. Brice,et al.  What genetics tells us about the causes and mechanisms of Parkinson's disease. , 2011, Physiological reviews.

[22]  C. Concannon,et al.  On the role of Hsp27 in regulating apoptosis , 2004, Apoptosis.

[23]  C. Wells,et al.  Disease-specific, neurosphere-derived cells as models for brain disorders , 2010, Disease Models & Mechanisms.

[24]  C. Olanow,et al.  The pathogenesis of cell death in Parkinson's disease , 2006, Neurology.

[25]  Ted M. Dawson,et al.  Genetic Animal Models of Parkinson's Disease , 2010, Neuron.

[26]  Guido Kroemer,et al.  Hsp27 negatively regulates cell death by interacting with cytochrome c , 2000, Nature Cell Biology.

[27]  Mancheva-Ganeva Velina,et al.  Licensed under Creative Commons Attribution Cc by Oxidative Stress in Parkinson's Disease , 2022 .

[28]  A. Mackay-Sim,et al.  Isolation of adult stem cells from the human olfactory mucosa. , 2013, Methods in molecular biology.

[29]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[30]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.

[31]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[32]  P. Srivastava,et al.  Heat‐Shock Proteins , 2003, Current protocols in immunology.

[33]  E. Parati,et al.  Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease. , 1993, Biochemical medicine and metabolic biology.

[34]  M. Farrer Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[35]  K. Schulze-Osthoff,et al.  Small Stress Proteins as Novel Regulators of Apoptosis , 1996, The Journal of Biological Chemistry.

[36]  W. Kunz,et al.  Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients , 2004, Journal of the Neurological Sciences.

[37]  C. Moraes,et al.  Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology* , 1999, The Journal of Biological Chemistry.

[38]  Michaela E Johnson,et al.  An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. , 2015, Neurotoxicology.

[39]  A. J. Lambert,et al.  Inhibitors of the Quinone-binding Site Allow Rapid Superoxide Production from Mitochondrial NADH:Ubiquinone Oxidoreductase (Complex I)* , 2004, Journal of Biological Chemistry.

[40]  Philip L De Jager,et al.  Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.

[41]  A. Schapira,et al.  Mitochondrial Contribution to Parkinson's Disease Pathogenesis , 2011, Parkinson's disease.

[42]  W. Kunz,et al.  Detection of Respiratory Chain Defects in Cultivated Skin Fibroblasts and Skeletal Muscle of Patients with Parkinson's Disease , 1999, Annals of the New York Academy of Sciences.

[43]  L. Montero,et al.  Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology , 2009, Neurobiology of Disease.

[44]  O. Blin,et al.  Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy , 1994, Journal of the Neurological Sciences.

[45]  T. Nishioka,et al.  Mode of inhibitory action of Deltalac-acetogenins, a new class of inhibitors of bovine heart mitochondrial complex I. , 2006, Biochemistry.

[46]  Piu Chan,et al.  Epidemiology of Parkinson's disease , 2016 .

[47]  E. Solary,et al.  HSP27 inhibits cytochrome c‐dependent activation of procaspase‐9 , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  J. Langston,et al.  The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.

[49]  N. Hattori,et al.  [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[50]  A. Kurz,et al.  Parkinson patient fibroblasts show increased alpha-synuclein expression , 2008, Experimental Neurology.

[51]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[52]  N. Wood,et al.  Expanding insights of mitochondrial dysfunction in Parkinson's disease , 2006, Nature Reviews Neuroscience.

[53]  E. Schon,et al.  Mitochondria: The Next (Neurode)Generation , 2011, Neuron.

[54]  M. Yahr,et al.  Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[55]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[56]  W. Tatton,et al.  Mitochondria in neurodegenerative apoptosis: An opportunity for therapy? , 1998, Annals of neurology.

[57]  Patrick A. Lewis,et al.  Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus , 2011, Nature communications.

[58]  A. Brice,et al.  Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.

[59]  J. Langston,et al.  Can cellular models revolutionize drug discovery in Parkinson's disease? , 2009, Biochimica et biophysica acta.

[60]  C. Páyan-Gomez,et al.  Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease. , 2014, Biochimica et biophysica acta.

[61]  A. Schapira,et al.  Test for LRRK2 mutations in patients with Parkinson’s disease , 2008, Practical Neurology.

[62]  B. Chauffert,et al.  HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. , 1997, Cancer research.

[63]  M. Beal,et al.  Mitochondria take center stage in aging and neurodegeneration , 2005, Annals of neurology.

[64]  M. Memo,et al.  Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease , 2012, EMBO molecular medicine.